Drug intelligence / Profile preview

FLQ-106

Development stage: Preclinical
Lead developer: FELIQS
Modality: Small Molecules
Administration: Ophthalmic

Overview

FLQ-106 is an investigational small molecule eye drop being developed by FELIQS for the treatment of pterygium. Pterygium is a common ocular surface disease characterized by the benign, fleshy growth of the conjunctiva onto the cornea, which can lead to irritation, inflammation, and visual impairment. FLQ-106 is currently in the IND-enabling phase of development. While the specific molecular target of FLQ-106 has not been publicly disclosed, the drug is part of FELIQS's portfolio focusing on small molecule therapeutics that address oxidative stress and lipid peroxidation pathways in ocular tissues.

Beyond the preview

Go deeper on FLQ-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLQ-106.

Explore the full profile